What percentage of Cologuard (multi-target stool DNA test) positive results correspond to colorectal cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Positive Predictive Value of Cologuard for Colorectal Cancer

Among patients with a positive Cologuard test who undergo follow-up colonoscopy, approximately 1-6% are found to have colorectal cancer, with the majority of positive results representing false positives or advanced adenomas rather than cancer.

Understanding the Numbers

The pivotal FDA approval trial of 9,989 participants established that Cologuard has a 92% sensitivity for detecting colorectal cancer 1, 2. However, the critical question you're asking relates to the positive predictive value (PPV)—what percentage of positive Cologuard tests actually represent cancer.

Key Performance Metrics from Guidelines

From the pivotal trial data 1:

  • Specificity: 87% (meaning 13% false positive rate among those without advanced lesions)
  • PPV for cancer or advanced precursor lesions combined: 27.3% 3
  • This means approximately 73% of positive Cologuard tests are false positives for advanced disease

Real-World Clinical Data

Recent real-world studies provide more granular data on what positive Cologuard tests actually reveal:

Cancer Detection Rates:

  • 0.2-6% of positive tests show colorectal cancer on follow-up colonoscopy 4, 5, 6, 7
  • Most studies cluster around 1-2.5% cancer detection 4, 6, 3
  • One large community practice found 4% cancer rate among positive tests 4

Advanced Adenoma Detection:

  • 24-33% of positive tests reveal advanced adenomas 4, 6, 3
  • Combined cancer + advanced adenomas: approximately 25-35% of positive results

False Positive Reality:

  • 65-73% of positive Cologuard tests show no advanced neoplasia on colonoscopy 4, 3
  • Many patients have non-advanced adenomas or completely normal colonoscopies

Critical Clinical Pitfalls

Age-Related Specificity Decline

Specificity decreases significantly with age 1, 2:

  • Patients >65 years: specificity drops to 83%
  • This means older patients have higher false-positive rates
  • Consider this when counseling elderly patients about testing

The Follow-Up Problem

A major real-world concern is poor colonoscopy adherence after positive tests 5:

  • Only 44-65% of patients complete follow-up colonoscopy within 12 months 4, 5
  • This dramatically reduces the test's effectiveness in preventing cancer mortality
  • Any positive Cologuard MUST be followed by colonoscopy—this is non-negotiable 8, 9

Patients with Prior Normal Colonoscopy

For patients who had a previous normal colonoscopy and then test positive on Cologuard 10, 11:

  • 30% have advanced adenomas on follow-up
  • 0-1% have cancer
  • These patients have approximately half the odds of advanced findings compared to screening-naive patients 11
  • However, the absolute risk remains clinically meaningful

Practical Clinical Algorithm

When a patient has a positive Cologuard:

  1. Schedule colonoscopy within 6 months (preferably sooner) 12
  2. Do NOT repeat Cologuard or order additional stool tests
  3. Do NOT evaluate upper GI tract unless patient has specific upper GI symptoms 1
  4. Counsel patient on expected findings:
    • ~1-4% chance of cancer
    • ~25-30% chance of advanced adenomas
    • ~65-70% chance of no advanced disease (but colonoscopy still mandatory)

If colonoscopy is negative after positive Cologuard:

  • Do not pursue further GI workup in asymptomatic patients 1
  • Resume routine screening intervals based on colonoscopy findings
  • The positive Cologuard does NOT indicate increased risk of aerodigestive cancers 1

Bottom Line for Clinical Practice

The answer to your question: approximately 1-4% of positive Cologuard tests represent colorectal cancer in real-world practice, with most positive results (65-73%) being false positives for advanced disease. However, 24-33% will have advanced adenomas, making follow-up colonoscopy essential. The test's value lies in its high sensitivity for cancer (92%), but clinicians must counsel patients about the high false-positive rate and the absolute necessity of colonoscopy follow-up to complete the screening process 1, 9, 12.

References

Guideline

colorectal cancer screening, version 1.2015.

Journal of the National Comprehensive Cancer Network : JNCCN, 2015

Research

Multitarget Stool DNA Testing Has High Positive Predictive Value for Colorectal Neoplasia on the Second Round of Testing.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.